Mamta K. Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Mamta K. Jain has a total of 501 co-authors. Here are the top co-authors by number of shared publications:
William M. Lee
UT Southwestern Medical Center, Department of Internal Medicine, Dallas, Texas, USA
7 shared publicationsNahid Attar
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas
5 shared publicationsXilong Li
Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States
4 shared publicationsAmit G. Singal
Parkland Health and Hospital System, Dallas, Texas; Department of Internal Medicine, Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas; Department of Internal Medicine, Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas
3 shared publicationsHejun Yuan
3 shared publicationsMae Thamer
Medical Technology and Practice Patterns Institute , Bethesda, Maryland , USA
3 shared publications
Latest Publications
- 1 May 2026
- Vol. 116 (5) , 732-735
Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.
Objectives. To estimate the increase in HIV infections in 11 US states if Ryan White services are interrupted or ended. Methods. We applied a population-level model of HIV transmission to 11 states. We represented the proportion of people with HIV receiving Ryan White AIDS drug assistance, outpatient health services, or support services, and simulated a loss of suppression in each category if services permanently end or return after delays of 1.5 or 3.5 years. Results. Cessation of Ryan White services in 2025 was projected to result in 69 695 additional infections from 2025 to 2030 (95% credible interval [CrI] = 18 943, 123 628), 68% more (95% CrI = 18%, 118%) than if Ryan White were continued. Temporary interruptions of 1.5 and 3.5 years resulted in 26 951 (95% CrI = 7341, 47 534) and 53 594 (95% CrI = 14 645, 94 860) additional infections, respectively. Excess infections varied across states, from a 45% increase in Texas to 126% in Missouri. Conclusions. Projected increases in HIV infections because of disruptions of Ryan White services threaten the progress made in curtailing the US HIV epidemic, illustrating the critical role Ryan White plays in preventing HIV transmission. (Am J Public Health. 2026;116(5):732-735. https://doi.org/10.2105/AJPH.2025.308409).
- 1 May 2026
- Vol. 116 (5) , 732-735
Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.
Objectives. To estimate the increase in HIV infections in 11 US states if Ryan White services are interrupted or ended. Methods. We applied a population-level model of HIV transmission to 11 states. We represented the proportion of people with HIV receiving Ryan White AIDS drug assistance, outpatient health services, or support services, and simulated a loss of suppression in each category if services permanently end or return after delays of 1.5 or 3.5 years. Results. Cessation of Ryan White services in 2025 was projected to result in 69 695 additional infections from 2025 to 2030 (95% credible interval [CrI] = 18 943, 123 628), 68% more (95% CrI = 18%, 118%) than if Ryan White were continued. Temporary interruptions of 1.5 and 3.5 years resulted in 26 951 (95% CrI = 7341, 47 534) and 53 594 (95% CrI = 14 645, 94 860) additional infections, respectively. Excess infections varied across states, from a 45% increase in Texas to 126% in Missouri. Conclusions. Projected increases in HIV infections because of disruptions of Ryan White services threaten the progress made in curtailing the US HIV epidemic, illustrating the critical role Ryan White plays in preventing HIV transmission. (Am J Public Health. 2026;116(5):732-735. https://doi.org/10.2105/AJPH.2025.308409).
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 59-69
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial
Background: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. Methods: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the days to recovery scale through day 60 (DRS-60), analyzed using a Van Elteren test. Results: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (P = .19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; P < .001). There was no difference in secondary clinical outcomes or prespecified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. Conclusions: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared with earlier periods in the COVID-19 pandemic and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 59-69
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial
Background: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. Methods: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the days to recovery scale through day 60 (DRS-60), analyzed using a Van Elteren test. Results: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (P = .19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; P < .001). There was no difference in secondary clinical outcomes or prespecified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. Conclusions: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared with earlier periods in the COVID-19 pandemic and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (3) , 671-679
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood. Participants enrolled in the Therapeutics for Inpatients with COVID-19 trials were randomized to nmAb versus placebo. Longitudinal differences between treatment and placebo groups in levels of plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein, interleukin-6, and D-dimer at enrollment, day 1, 3, and 5 were estimated using linear mixed models. A 7-point pulmonary ordinal scale assessed at day 5 was compared using proportional odds models. Analysis included 2149 participants enrolled between August 2020 and September 2021. Treatment resulted in 20% lower levels of plasma N-Ag compared with placebo (95% confidence interval, 12%–27%; P < .001), and a steeper rate of decline through the first 5 days (P < .001). The treatment difference did not vary between subgroups, and no difference was observed in trajectories of other biomarkers or the day 5 pulmonary ordinal scale. Our study suggests that nmAb has an antiviral effect assessed by plasma N-Ag among hospitalized patients with COVID-19, with no blunting of the endogenous anti-nucleocapsid antibody response. No effect on systemic inflammation or day 5 clinical status was observed. NCT04501978.
- 9 November 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (3) , 671-679
Open AccessEffect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood. Participants enrolled in the Therapeutics for Inpatients with COVID-19 trials were randomized to nmAb versus placebo. Longitudinal differences between treatment and placebo groups in levels of plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein, interleukin-6, and D-dimer at enrollment, day 1, 3, and 5 were estimated using linear mixed models. A 7-point pulmonary ordinal scale assessed at day 5 was compared using proportional odds models. Analysis included 2149 participants enrolled between August 2020 and September 2021. Treatment resulted in 20% lower levels of plasma N-Ag compared with placebo (95% confidence interval, 12%–27%; P < .001), and a steeper rate of decline through the first 5 days (P < .001). The treatment difference did not vary between subgroups, and no difference was observed in trajectories of other biomarkers or the day 5 pulmonary ordinal scale. Our study suggests that nmAb has an antiviral effect assessed by plasma N-Ag among hospitalized patients with COVID-19, with no blunting of the endogenous anti-nucleocapsid antibody response. No effect on systemic inflammation or day 5 clinical status was observed. NCT04501978.
- Open Access
- 24 July 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (14)
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
BACKGROUND: Antibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients with influenza B but showed no benefit for influenza A. METHODS: To probe potential mechanisms of Flu-IVIG utility, sera collected from patients hospitalized with influenza A or B viruses (IAV or IBV) were analyzed for antibody isotype/subclass and Fcγ receptor (FcγR) binding by ELISA, bead-based multiplex, and NK cell activation assays. RESULTS: Influenza-specific FcγR-binding antibodies were elevated in Flu-IVIG–infused IBV- and IAV-infected patients. In IBV-infected participants ( n = 62), increased IgG3 and FcγR binding were associated with more favorable outcomes. Flu-IVIG therapy also improved the odds of a more favorable outcome in patients with low levels of anti-IBV Fc-functional antibody. Higher FcγR-binding antibody was associated with less favorable outcomes in IAV-infected patients ( n = 50), and Flu-IVIG worsened the odds of a favorable outcome in participants with low levels of anti-IAV Fc-functional antibody. CONCLUSION: These detailed serological analyses provide insights into antibody features and mechanisms required for a successful humoral response against influenza, suggesting that IBV-specific, but not IAV-specific, antibodies with Fc-mediated functions may assist in improving influenza outcome. This work will inform development of improved influenza immunotherapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02287467. FUNDING: Funding for this research was provided by subcontract 13XS134 under Leidos Biomedical Research Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID.
- 24 July 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (14)
Open AccessUnderstanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
BACKGROUND: Antibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients with influenza B but showed no benefit for influenza A. METHODS: To probe potential mechanisms of Flu-IVIG utility, sera collected from patients hospitalized with influenza A or B viruses (IAV or IBV) were analyzed for antibody isotype/subclass and Fcγ receptor (FcγR) binding by ELISA, bead-based multiplex, and NK cell activation assays. RESULTS: Influenza-specific FcγR-binding antibodies were elevated in Flu-IVIG–infused IBV- and IAV-infected patients. In IBV-infected participants ( n = 62), increased IgG3 and FcγR binding were associated with more favorable outcomes. Flu-IVIG therapy also improved the odds of a more favorable outcome in patients with low levels of anti-IBV Fc-functional antibody. Higher FcγR-binding antibody was associated with less favorable outcomes in IAV-infected patients ( n = 50), and Flu-IVIG worsened the odds of a favorable outcome in participants with low levels of anti-IAV Fc-functional antibody. CONCLUSION: These detailed serological analyses provide insights into antibody features and mechanisms required for a successful humoral response against influenza, suggesting that IBV-specific, but not IAV-specific, antibodies with Fc-mediated functions may assist in improving influenza outcome. This work will inform development of improved influenza immunotherapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02287467. FUNDING: Funding for this research was provided by subcontract 13XS134 under Leidos Biomedical Research Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID.
- Open Access
- 17 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad375
Who Is at Risk for New Hepatitis B Infections Among People With HIV?
Hepatitis B virus (HBV) increases morbidity and mortality among people with HIV (PWH). We retrospectively analyzed HBV incidence among 5785 PWH. Fourteen had newly positive hepatitis B s antigen (mean 5.2 person-years of follow-up, 46.4/100 000 infections/year). These data show gaps in HBV vaccination and in the preventative efficacy of HBV-specific antiretroviral therapy.
- 17 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad375
Open AccessWho Is at Risk for New Hepatitis B Infections Among People With HIV?
Hepatitis B virus (HBV) increases morbidity and mortality among people with HIV (PWH). We retrospectively analyzed HBV incidence among 5785 PWH. Fourteen had newly positive hepatitis B s antigen (mean 5.2 person-years of follow-up, 46.4/100 000 infections/year). These data show gaps in HBV vaccination and in the preventative efficacy of HBV-specific antiretroviral therapy.
- Open Access
- 4 July 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (10) , 790-792
Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?
Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.
- 4 July 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (10) , 790-792
Open AccessPersistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?
Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.
- Open Access
- 4 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (13) , e027273
Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort
Background: Cardiovascular disease risk prediction models underestimate CVD risk in people living with HIV (PLWH). Our goal is to derive a risk score based on protein biomarkers that could be used to predict CVD in PLWH. Methods and Results: In a matched case–control study, we analyzed normalized protein expression data for participants enrolled in 1 of 4 trials conducted by INSIGHT (International Network for Strategic Initiatives in Global HIV Trials). We used dimension reduction, variable selection and resampling methods, and multivariable conditional logistic regression models to determine candidate protein biomarkers and to generate a protein score for predicting CVD in PLWH. We internally validated our findings using bootstrap. A protein score that was derived from 8 proteins (including HGF [hepatocyte growth factor] and interleukin‐6) was found to be associated with an increased risk of CVD after adjustment for CVD and HIV factors (odds ratio: 2.17 [95% CI: 1.58–2.99]). The protein score improved CVD prediction when compared with predicting CVD risk using the individual proteins that comprised the protein score. Individuals with a protein score above the median score were 3.10 (95% CI, 1.83–5.41) times more likely to develop CVD than those with a protein score below the median score. Conclusions: A panel of blood biomarkers may help identify PLWH at a high risk for developing CVD. If validated, such a score could be used in conjunction with established factors to identify CVD at‐risk individuals who might benefit from aggressive risk reduction, ultimately shedding light on CVD pathogenesis in PLWH.
- 4 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (13) , e027273
Open AccessDerivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort
Background: Cardiovascular disease risk prediction models underestimate CVD risk in people living with HIV (PLWH). Our goal is to derive a risk score based on protein biomarkers that could be used to predict CVD in PLWH. Methods and Results: In a matched case–control study, we analyzed normalized protein expression data for participants enrolled in 1 of 4 trials conducted by INSIGHT (International Network for Strategic Initiatives in Global HIV Trials). We used dimension reduction, variable selection and resampling methods, and multivariable conditional logistic regression models to determine candidate protein biomarkers and to generate a protein score for predicting CVD in PLWH. We internally validated our findings using bootstrap. A protein score that was derived from 8 proteins (including HGF [hepatocyte growth factor] and interleukin‐6) was found to be associated with an increased risk of CVD after adjustment for CVD and HIV factors (odds ratio: 2.17 [95% CI: 1.58–2.99]). The protein score improved CVD prediction when compared with predicting CVD risk using the individual proteins that comprised the protein score. Individuals with a protein score above the median score were 3.10 (95% CI, 1.83–5.41) times more likely to develop CVD than those with a protein score below the median score. Conclusions: A panel of blood biomarkers may help identify PLWH at a high risk for developing CVD. If validated, such a score could be used in conjunction with established factors to identify CVD at‐risk individuals who might benefit from aggressive risk reduction, ultimately shedding light on CVD pathogenesis in PLWH.
- 29 November 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (12) , 1716-1727
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial
The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. In this post hoc analysis of a series of phase 3 trials that evaluated ... Visual Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults. The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time... Background: The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. Objective: To evaluate whether recovery and mortality improved ...
- 29 November 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (12) , 1716-1727
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial
The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. In this post hoc analysis of a series of phase 3 trials that evaluated ... Visual Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults. The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time... Background: The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. Objective: To evaluate whether recovery and mortality improved ...
- Open Access
Host Cell Redox Alterations Promote Latent HIV-1 Reactivation through Atypical Transcription Factor Cooperativity
Immune cell state alterations rewire HIV-1 gene expression, thereby influencing viral latency and reactivation, but the mechanisms are still unfolding. Here, using a screen approach on CD4+ T cell models of HIV-1 latency, we revealed Small Molecule Reactivators (SMOREs) with unique chemistries altering the CD4+ T cell state and consequently promoting latent HIV-1 transcription and reactivation through an unprecedented mechanism of action. SMOREs triggered rapid oxidative stress and activated a redox-responsive program composed of cell-signaling kinases (MEK-ERK axis) and atypical transcription factor (AP-1 and HIF-1α) cooperativity. SMOREs induced an unusual AP-1 phosphorylation signature to promote AP-1/HIF-1α binding to the latent HIV-1 proviral genome for its activation. Consistently, latent HIV-1 reactivation was compromised with pharmacologic inhibition of oxidative stress sensing or of cell-signaling kinases, and transcription factor’s loss of expression, thus functionally linking the host redox-responsive program to viral transcriptional rewiring. Notably, SMOREs induced the redox program in primary CD4+ T cells and reactivated latent HIV-1 in aviremic patient samples alone and in combination with known latency-reversing agents, thus providing physiological relevance. Our findings suggest that manipulation of redox-sensitive pathways could be exploited to alter the course of HIV-1 latency, thus rendering host cells responsive to help achieve a sterilizing cure.
Open AccessHost Cell Redox Alterations Promote Latent HIV-1 Reactivation through Atypical Transcription Factor Cooperativity
Immune cell state alterations rewire HIV-1 gene expression, thereby influencing viral latency and reactivation, but the mechanisms are still unfolding. Here, using a screen approach on CD4+ T cell models of HIV-1 latency, we revealed Small Molecule Reactivators (SMOREs) with unique chemistries altering the CD4+ T cell state and consequently promoting latent HIV-1 transcription and reactivation through an unprecedented mechanism of action. SMOREs triggered rapid oxidative stress and activated a redox-responsive program composed of cell-signaling kinases (MEK-ERK axis) and atypical transcription factor (AP-1 and HIF-1α) cooperativity. SMOREs induced an unusual AP-1 phosphorylation signature to promote AP-1/HIF-1α binding to the latent HIV-1 proviral genome for its activation. Consistently, latent HIV-1 reactivation was compromised with pharmacologic inhibition of oxidative stress sensing or of cell-signaling kinases, and transcription factor’s loss of expression, thus functionally linking the host redox-responsive program to viral transcriptional rewiring. Notably, SMOREs induced the redox program in primary CD4+ T cells and reactivated latent HIV-1 in aviremic patient samples alone and in combination with known latency-reversing agents, thus providing physiological relevance. Our findings suggest that manipulation of redox-sensitive pathways could be exploited to alter the course of HIV-1 latency, thus rendering host cells responsive to help achieve a sterilizing cure.